Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab

Leuk Res. 2021 May:104:106571. doi: 10.1016/j.leukres.2021.106571. Epub 2021 Mar 30.

Authors

Ewa Robak¹, Dorota Jesionek-Kupnicka², Elzbieta Iskierka-Jazdzewska³, Agnieszka Janus³, Tadeusz Robak⁴

Affiliations

¹ Department of Dermatology, Medical University of Lodz, Lodz, Poland.
² Department of Pathology, Chair of Oncology, Medical University of Lodz, Lodz, Poland.
³ Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.
⁴ Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland. Electronic address: robaktad@csk.umed.lodz.pl.

PMID: 33831657
DOI: 10.1016/j.leukres.2021.106571

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Hairy Cell* / diagnosis
Leukemia, Hairy Cell* / drug therapy
Leukemia, Hairy Cell* / pathology
Male
Middle Aged
Rituximab / administration & dosage*
Vasculitis, Leukocytoclastic, Cutaneous* / diagnosis
Vasculitis, Leukocytoclastic, Cutaneous* / drug therapy
Vasculitis, Leukocytoclastic, Cutaneous* / pathology
Vemurafenib / administration & dosage*

Substances

Vemurafenib
Rituximab